For years, Australian pet parents have faced a quiet frustration: the products their vets recommend for flea, worm and heartworm protection work exceptionally well, but they come at a price that makes monthly compliance feel like a luxury. At the same time, veterinary professionals have watched their clients skip doses, delay treatments, or simply go without, not because they don’t care about their pets, but because the economics don’t always add up. Abbey was built to change that equation.
ExiFlea Plus is a monthly spot-on treatment that protects dogs and cats against fleas, intestinal worms, heartworm and ear mites in a single application. It uses the same clinically established active ingredients, imidacloprid and moxidectin, that have been the gold standard in companion animal parasiticide treatment for over two decades. Same actives. Same efficacy. A price that makes year-round protection genuinely accessible. Available across the full weight range from small breeds to extra-large dogs, and small and large cats, ExiFlea Plus is designed to make the decision to protect your pet the easiest decision you make all month.
Australia has one of the highest rates of pet ownership in the world. More than 60 per cent of Australian households share their home with a pet, and the bond between Australians and their pets has never been stronger, or more evident than it was through the years of the pandemic, when pets became an anchor for millions of families. Yet companion animal health remains a category where access and affordability are genuine barriers. Premium parasiticide brands dominate vet clinic shelves, and the price gap between those brands and effective protection has remained stubbornly wide. Independent pet parents, particularly those in regional and rural Australia, where heartworm risk is highest and vet access can be limited, often bear the brunt of that gap. We have spent considerable time studying this area and ExiFlea Plus is the result of that analysis. A product developed with clinical rigour and priced with the Australian pet parent and vet practices in mind.
There is more to follow. We are building a portfolio with a clear and consistent logic: take the active ingredients and clinical evidence base that veterinary science has established as effective, and make the resulting protection available to more Australian pets. Not through shortcuts, not through compromise on quality, but through a different commercial model. One that doesn’t require a premium brand margin to fund a category we believe should simply work better.